Market Overview:
The global diabetic retinopathy market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of diabetes, rising awareness about diabetic retinopathy, and technological advancements in the field of laser surgery and anti-VEGF drugs. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. On the basis of type, laser surgery is expected to account for a major share of the global diabetic retinopathy market during the forecast period. This can be attributed to its advantages over other treatment options such as injection of corticosteroids and vitrectomy. Oncology lasers are increasingly being used for treating various eye diseases including diabetic retinopathy owing to their superior capabilities such as precision and accuracy. Oncology lasers are increasingly being used for treating various eye diseases including diabetic retinopathy owing to their superior capabilities such as precision.
Product Definition:
Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. It is caused by damage to the blood vessels of the retina, often resulting from long-term diabetes.
Laser Surgery:
Laser surgery is a minimally invasive technique that uses concentrated light energy to treat the retina. The retina is the tissue in the back of the eye responsible for vision. In diabetic retinopathy, there are blood vessels leakage which may lead to blindness if not treated at an early stage. Laser surgery can be used for treating this condition by sealing or removing leaky blood vessels thus improving patient’s vision.
Injection of Corticosteroids:
Injection of corticosteroids is used in the treatment of diabetic retinopathy. Corticosteroid injections are useful for reducing inflammation and improving vision. The most commonly used injectable corticosteroid is prednisolone acetate; it is administered every 3 to 4 weeks in the treatment of diabetic retinopathy.
Application Insights:
Based on application, the global market is segmented into hospitals, clinics and ophthalmic centers, and others. Hospitals held the largest share in 2017 as they are considered to be a primary care facility for diabetic retinopathy patients. As per an article published by NCBI in 2018, majority of retinal laser surgery procedures are performed in hospital settings as compared to other settings such as clinics or ophthalmic centers. This factor is anticipated to boost product demand over the forecast period.
The others segment includes non-hospital based facilities that offer treatment for diabetic retinopathy such as private practices and vision correction centers.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of diabetes, presence of sophisticated healthcare infrastructure, and availability of technologically advanced devices are some factors responsible for its large share. Moreover, increasing government initiatives to create awareness regarding retinopathy is also expected to drive the regional market during the forecast period. For instance, The American Academy of Ophthalmology (AAO) launched a campaign in 2016 called My Eyes!, which educates people about early detection and treatment options for diabetic retinopathy so that they can live a better quality life with minimal vision problems.
Asia Pacific is expected to grow at an exponential rate over the forecast period owing to rising geriatric population coupled with growing prevalence of diabetes in this region.
Growth Factors:
- Increasing prevalence of diabetes: The number of people with diabetes is increasing at an alarming rate across the globe. This will lead to an increase in the incidence of diabetic retinopathy, thereby driving the market growth.
- Rising awareness about diabetic retinopathy: There is a growing awareness among people about diabetic retinopathy and its symptoms. This is likely to result in more people getting diagnosed and treated for the condition, propelling market growth.
- Technological advancements in treatment options: There has been a significant advancement in treatment options for diabetic retinopathy over the past few years. This is likely to drive demand for these treatments, leading to market growth.
- Growing geriatric population: The geriatric population (aged 65 years or above) is growing at a rapid pace worldwide and they are highly susceptible to developing diabetic retinopathy .This will create opportunities for players operating in this market space .
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Retinopathy Market Research Report
By Type
Laser Surgery, Injection of Corticosteroids, Anti-VEGF Drugs, Vitrectomy
By Application
Hospitals, Clinics, Others
By Companies
Bayer, Roche, Novartis, TEVA, Alimera Sciences, Regeneron Pharmaceuticals, Boehringer Ingelheim, Kowa Group, Ohr Pharmaceutical, Quark Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Retinopathy Market Report Segments:
The global Diabetic Retinopathy market is segmented on the basis of:
Types
Laser Surgery, Injection of Corticosteroids, Anti-VEGF Drugs, Vitrectomy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Roche
- Novartis
- TEVA
- Alimera Sciences
- Regeneron Pharmaceuticals
- Boehringer Ingelheim
- Kowa Group
- Ohr Pharmaceutical
- Quark Pharmaceuticals
Highlights of The Diabetic Retinopathy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Laser Surgery
- Injection of Corticosteroids
- Anti-VEGF Drugs
- Vitrectomy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Retinopathy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetic retinopathy is a complication of diabetes that can cause vision problems. It develops when blood vessels in the eye become damaged from high blood sugar levels. The damage can make it difficult for the eyes to receive enough oxygen and nutrients, which can lead to blindness.
Some of the major players in the diabetic retinopathy market are Bayer, Roche, Novartis, TEVA, Alimera Sciences, Regeneron Pharmaceuticals, Boehringer Ingelheim, Kowa Group, Ohr Pharmaceutical, Quark Pharmaceuticals.
The diabetic retinopathy market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Diabetic Retinopathy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Diabetic Retinopathy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Diabetic Retinopathy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Diabetic Retinopathy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Diabetic Retinopathy Market Size & Forecast, 2018-2028
4.5.1 Diabetic Retinopathy Market Size and Y-o-Y Growth
4.5.2 Diabetic Retinopathy Market Absolute $ Opportunity
Chapter 5 Global Diabetic Retinopathy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Diabetic Retinopathy Market Size Forecast by Type
5.2.1 Laser Surgery
5.2.2 Injection of Corticosteroids
5.2.3 Anti-VEGF Drugs
5.2.4 Vitrectomy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Diabetic Retinopathy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Diabetic Retinopathy Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Diabetic Retinopathy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Diabetic Retinopathy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Diabetic Retinopathy Analysis and Forecast
9.1 Introduction
9.2 North America Diabetic Retinopathy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Diabetic Retinopathy Market Size Forecast by Type
9.6.1 Laser Surgery
9.6.2 Injection of Corticosteroids
9.6.3 Anti-VEGF Drugs
9.6.4 Vitrectomy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Diabetic Retinopathy Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Diabetic Retinopathy Analysis and Forecast
10.1 Introduction
10.2 Europe Diabetic Retinopathy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Diabetic Retinopathy Market Size Forecast by Type
10.6.1 Laser Surgery
10.6.2 Injection of Corticosteroids
10.6.3 Anti-VEGF Drugs
10.6.4 Vitrectomy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Diabetic Retinopathy Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Diabetic Retinopathy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Diabetic Retinopathy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Diabetic Retinopathy Market Size Forecast by Type
11.6.1 Laser Surgery
11.6.2 Injection of Corticosteroids
11.6.3 Anti-VEGF Drugs
11.6.4 Vitrectomy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Diabetic Retinopathy Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Diabetic Retinopathy Analysis and Forecast
12.1 Introduction
12.2 Latin America Diabetic Retinopathy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Diabetic Retinopathy Market Size Forecast by Type
12.6.1 Laser Surgery
12.6.2 Injection of Corticosteroids
12.6.3 Anti-VEGF Drugs
12.6.4 Vitrectomy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Diabetic Retinopathy Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Diabetic Retinopathy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Diabetic Retinopathy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Diabetic Retinopathy Market Size Forecast by Type
13.6.1 Laser Surgery
13.6.2 Injection of Corticosteroids
13.6.3 Anti-VEGF Drugs
13.6.4 Vitrectomy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Diabetic Retinopathy Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Diabetic Retinopathy Market: Competitive Dashboard
14.2 Global Diabetic Retinopathy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Roche
14.3.3 Novartis
14.3.4 TEVA
14.3.5 Alimera Sciences
14.3.6 Regeneron Pharmaceuticals
14.3.7 Boehringer Ingelheim
14.3.8 Kowa Group
14.3.9 Ohr Pharmaceutical
14.3.10 Quark Pharmaceuticals
